Alio (San Francisco, CA, USA) is an early commercial stage company who believes it is time we tap into the opportunity to revolutionize today’s tools for remote patient monitoring.  The technologies in the current market are invasive, expensive, often provide inadequate data and do not deliver a positive user experience.  Re-imagining what care looks like for those facing dialysis and heart failure has been done before, but the execution has failed. We understand chronic conditions do not merely require episodic care, but rather reliable and clinically accurate remote patient monitoring seamlessly integrating itself into a patient’s day to day life.

Therapeutic: Remote Patient Monitoring

Allotex (Boston, MA, USA) Better Near Vision for Presbyopic Patients with the use of Allogeneic Corneal Tissue. The Allotex TransForm Corneal Inlay is a tiny implant, thinner than a human hair that optimizes the optics of the cornea improving near vision. The technology uses precisely-shaped human corneal allografts to create what is essentially a permanent, living "contact lens" insert.

Therapeutic: Ophthalmology & Presbyopia Correction

Alucent Biomedical (Salt Lake City, UT, USA) is a privately held biomedical company focused on our vision to transform the way vascular disease is treated. We are focused on using advanced technology to harness the body’s own natural physiologic processes and structures. Natural Vascular Scaffolding™ (NVS) is a breakthrough technology being developed to address the unmet need of patients with difficult-to-treat peripheral artery disease (PAD). It is the first technology of its kind that uses photoactivated protein linking to potentially restore vessels and provide durable patency without stents or other implants.

Therapeutic: Cardiovascular

Artiria Medical (Geneva, Switzerland) Today the best option to treat stroke consists in employing the patient vascular system as an access route to deliver a treatment in the brain. Although 230’000 such procedures are carried out every year, current interventional devices do not provide sufficient control to the surgeon resulting in increased risk of complications, increased costs and increased surgery duration. We developed a micro-actuated device enabling a seamless treatment of neurovascular diseases with unprecedented accuracy, effectiveness and safety.

Therapeutic: Neurovascular

Askel Healthcare Ltd (Helsinki, Finland) offers a unique way to rebuild joint surfaces for pain-free movement. COPLA® is an implantable medical device for cartilage repair in weight-bearing joints. The weight-adaptive matrix is tailored for load transfer as well as nutrition transport – both features are essential factors for cartilage formation. COPLA® has already shown its potential in veterinary patients. The company estimates COPLA® will be available for human patients in 2024.

Therapeutic: Regenerative Medicine

ASPIVIX (Renens, Switzerland) We are Women's Healthcare company developing modern medical devices for gynecology. Our flagship product - an atraumatic suction cervix holder – eliminates pain and bleeding caused by the tenaculum, a device developed a century ago and used in more than 80M common gynecological procedures annually. Moderate to severe trauma cause by the tenaculum is a significant barrier for both clinician and women adopt the Intrauterine Device, the most cost effective contraceptive in the market today. Effective contraceptives are key for tackling the unplanned pregnancy epidemic.

Therapeutic: Women’s Health, Contraception & IUD Insertion

AtriAN Medical (Galway, Ireland) is in preparation for first-in-human trials for treating Atrial Fibrillation (AFib) with a novel non-thermal approach using technology first explored by world-renowned clinicians in Mayo Clinic. AtriAN's technology uses specialized catheters delivering short pulses of low energy electrical fields to discrete sites of autonomic hyperactivity located on the outside surface of the heart. This selectively ablates these autonomic neuronal structures, providing a long-term resolution to AFib. AtriAN is an Irish company, based in Galway.

Therapeutic: Cardiovascular

CardiacBooster A.V. (Nijmegen, Netherlands) addresses the pVAD market with a novel device concept. With barely half of cardiogenic shock patients surviving despite support with current percutaneous ventricular assist devices (pVAD), a substantial unmet clinical need remains and time is ripe for innovation. CardiacBooster’s differentiated technology creates a powerful pump within the pump. The device increases stroke volume and cardiac output by actively ejecting blood from the left ventricle. The novel concept allows for a low-profile catheter design while preserving power, overcoming the trade-off existing devices have to make between pump power and size-related access complications.

Therapeutic: Cardiovascular

CardioRenal (Paris, France) is a company dedicated to improving the quality of treatment for heart failure patients through the use of state-of-the art technology (expert systems, real-time diagnosis, microfluidics, etc.) combined with top medical expertise.

Therapeutic: Cardiovascular

CroíValve (Dublin, Ireland) is an early stage medical device company focused on developing a percutaneous solution for severe tricuspid regurgitation which is safe, effective, easy to use & treats all patients.

Therapeutic: Cardiovascular

Cuspa Medical (Nazareth, Israel) Developer of an artificial cusp designed to eliminate the regurgitant orifice in cases of valve insufficency while maintaining normal valve function. The Cusper device offers a miminally invasive repair option for valve insufficency, specifically targeting aortic insufficency in a simple, inituative procedure expected to benefit a patient population with very few alternatives.

Therapeutic: Cardiovascular

Echopoint Medical (London, UK) is a spin-out from UCL, London, commercialising a series of novel optical sensing technologies. The first will be the iKOr™ Rx coronary microcatheter, delivered over any workhorse 0.014” guidewire to provide pressure (FFR, resting indices) and flow (e.g.CFR, IMR) with a solid-state sensor (no saline injection). The extreme low-profile microcatheter, straightforward console UI plus workflow provides key metrics with a negligible training requirement.

Therapeutic: Cardiovascular & Interventional Cardiology

emtensor (Fremont, CA, USA) produces a novel brain scanner for detecting ischemic and/or hemorrhagic brain conditions using a portable, safe, fast and early deployable functional brain imager that can radically reduce the time from onset to treatment in stroke from hours to minutes. Harmless non invasive radio frequency measurement coupled with a no moving part modality and no contrast agents is combined with full electromagnetic wave solution based tomography to identify regions of unhealthy tissue inside the skull from the tissues tell-tale relative permittivity characteristics.

Therapeutic: Stroke, Traumatic Brain Injury, Transient Ischemic Attack, Concussion & Brain Health

ErgoSuture (Boston, MA, USA) Drive'N Roll is an advanced suturing system with the simplicity of a regular needle driver that offers improved maneuverability and needle handling, short learning curve and shorter procedure times.

Therapeutic: Urology, Gynecology & Minimally Invasive Surgery

E-Scopics S.A.S (Aix-en-Provence, France) E-Scopics dematerializes Ultrasound to democratize its use to all healthcare professionals. Products are application specific Apps, downloadable on Tablets or Smartphones that connect to, and control smart digital probes. E-Scopics truly revolutionizes the field of Ultrasound, leveraging advance processing techniques and AI-based imaging algorithms. This allows ultra-low power consumption systems, addressing the key issue of all ultraportable systems on the market. E-Scopics further differentiates clinically with unique “imaging biomarkers” that standardize surveillance of chronic diseases, without acquisition skills nor interpretation expertise.

Therapeutic: Imaging & Diagnostics

Fasciotens (Cologne, Germany) was founded in 2016 by two surgeons, Gereon Lill and Frank Beyer. Fasciotens Abdomen has been developed to improve the treatment of the open abdomen. It couteracts abdominal wall retraction and shortens the treatment. For intraoperative expansion of ventral incisional hernias, Fasciotens Hernia is introduced now. The technique was published as a promising new approach in hernia surgery and is now facilitated with this ready-made solution. Fasciotens is growing in Europe and aims for market entry in the US.

Therapeutic: Surgery

FAST BioMedical (Indianapolis, IN, USA) is a privately held company developing late clinical-stage medical technologies. The company’s globally patented technology is designed to be the first to directly measure volume status and kidney function in a clinically actionable way. This technology has the potential for significant impact on the treatment of patients with heart failure, cardio-renal syndrome, major surgery, sepsis, and acute kidney injury.

Therapeutic: Cardiovascular & Precision Medicine

FEops HEARTguide (Gent, Belgium), currently available on the EU and Canadian market, is a one-in-its-kind cloud based procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning pre-operatively using novel computational modeling and simulation technology. Such insights have the power to help improving clinical outcomes in real-world hospital settings. The current release includes workflows for transcatheter aortic valve implantation (TAVI) and left atrial appendage occlusion (LAAo) procedures.

Therapeutic: Cardiovascular

IME Medical Electrospinning (Waalre, The Netherlands) is the global leader in fiber-based medical devices. We utilize our game-changing technology to free humanity from unnatural implants through our body-friendly nano-fibers which dissolve in time and get replaced by natural tissue. This way, we help the human body to heal itself.

Therapeutic: Biomaterials, Regenerative Medicine & Drug Delivery

Intelligent Implants (Houston, TX, USA) is introducing the first ever wireless implantable bioelectronic stimulation platform that is incorporated into standard orthopedic implants. We are able to get superior bone growth around our implant by electrically stimulating the bone to grow. We can sculpt the bone growth around the implant using current steering and we monitor the bone growth in real-time using impedance tomography. With excellent large animal trial outcomes, we are now looking to bring our breakthrough technology into the clinic.

Therapeutic: Orthopedics

iSTAR Medical (Wavre, Belgium) develops minimally invasive ophthalmic implants for the treatment of patients with glaucoma. MINIject, made of STAR® material, is iSTAR Medical’s revolutionary microinvasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile. MINIject enhances natural fluid outflow, reducing intraocular pressure and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. iSTAR Medical was founded in 2011.

Therapeutic: Ophthalmology

Lifelet Medical (Galway, Ireland) are developing a heart valve leaflet technology that transcends the existing limitations of heart valve replacements by disrupting the way heart valves are made. In providing sustainable, durable, cost-effective heart valve leaflet solutions, Lifelet aims to improve patient outcomes and prevent the need for costly re-intervention on millions of patients in the future. The Lifelet polymer is a biodurable synthetic material, USP Class VI, with excellent chronic pre-clinical performance and free from thrombus in animals without anticoagulation.

Therapeutic: Cardiovascular & Biomaterials

Lightpoint Medical (Cambridge, MA, USA) is developing miniaturized sensing and imaging tools for robot-assisted cancer surgery. The company has two robotic probe technologies in development which aim to aid surgical decision making, improve patient outcomes, and save costs for healthcare systems. Although applicable to a wide range of major cancer types, the first commercial focus is prostate cancer surgery. Lightpoint has secured over $17M in non-dilutive grants and $10M in private investment with early commercial sales in the UK, Netherlands, and Germany.

Therapeutic: Oncology

LimFlow (Paris, France) is a private, venture-backed medical device company transforming the treatment of chronic limb-threatening ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease, kidney disease and an aging population. The LimFlow pDVA system enables a minimally invasive procedure that bypasses unreconstructible arteries in the leg and brings oxygenated blood to the foot by reversing the flow in targeted veins. Successful reperfusion of the foot promotes wound healing and may prevent major amputation.

Therapeutic: Cardiovascular

Loop Medical (Lausanne, Switzerland) The COVID-19 crisis cruelly highlighted the need to improve access to clinical diagnosis. Loop Medical's vision is to simplify access to clinical-grade blood testing for everyone, everywhere, and to unlock the tremendous potential of home testing. We are developing a painless, easy-to-use sampling device that collects a large volume of high-quality capillary blood (1 mL vs. only 0.2 mL for competitors). It is supported by the Bill & Melinda Gates Foundation, by the Horizon 2020 programme and partners with Cerba Healthcare.

Therapeutic: Diagnostics

Medical Microinstruments SpA (MMI) (Pisa, Italy) was founded in 2015 to enhance surgical performance through the development of a robotic system that enables surgeons to achieve better outcomes on delicate microsurgical procedures. The MMI robotic platform combines proprietary innovations including the world’s smallest wristed microinstruments as well as tremor-reducing and motion scaling technologies. Together, these powerful capabilities allow more surgeons to successfully perform microsurgery while expanding the field of supermicosurgery.  

Therapeutic: Robotics & Surgery

Melio (London, UK and Madrid, Spain) is the health system that uses deep diagnostic knowledge to give you a more active relationship with your health. Melio will be the leader in health monitoring using blood biomarkers and immune signatures as a window on wellness.

Therapeutic: Biomarkers & Diagnostics

Minnetronix Medical (St. Paul, MN, USA) From complex engineering to finished devices, Minnetronix Medical applies expansive industry insight and international technical acumen to deliver better medical devices, faster. Its comprehensive and synergistic approach creates a seamless experience from project kickoff through product delivery, addressing supply chain, supporting and clearing the path to regulatory approval, and applying quality management disciplines. Minnetronix concepts whole product solutions, currently focused on neurocritical care, through commercialization for partners to leverage by advancing their technologies or expanding their bag of market-ready solutions.

Therapeutic: Medical Device Technology Partner

Monogram Orthopaedics (Austin, TX, USA) is ushering in the future of joint reconstruction. We combine 3D printing and robotics with automated digital image analysis algorithms to enable mass personalization of the next generation of orthopedic implants. We start by converting raw CT scans into smart CAD models using various computer vision techniques, including shape modeling and artificial intelligence (“AI”). Using sophisticated geometric modeling and simulation algorithms, we build implants that are optimized to restore anatomical function and solve real clinical problems.

Therapeutic: Orthopedics & Robotics

Newronika (Milan, Italy) AlphaDBS is the first closed-loop deep brain neuro-modulation system. AlphaDBS interprets the bioelectrical neuronal activity (local field potentials, LFPs) in the brain areas where stimulation is delivered and accordingly adapts moment-by-moment the stimulation to follow patient’s clinical condition. AlphaDBS sensing technology is able to record noise free LFPs while electrical stimulation is delivered. Although our first aim is Parkinson treatment, we want to become a platform to develop the first generation of functioning Brain Machine Interfaces.

Therapeutic: Neurology & Neuromodulation

ODS Medical Inc. (Montreal, Quebec, Canada) is dedicated to bringing the next generation of diagnostic tools to the hands of physicians by bringing together the power of machine learning and molecular imaging to develop optical biopsy tools based on Raman spectroscopy. The SentryTM system for real-time tissue characterization detects the presence of invasive cancer directly in patients, pushing the limits of cancer detection in many procedures. and empowering doctors to make critical decisions, in real-time, to improve patient safety and outcomes.

Therapeutic: Surgery

OrthoSon (Oxford, United Kingdom) is developing a truly percutaneous, safer and more cost-effective procedure for people living with persistent, discogenic low back pain. The technology is the result of 10 years of ongoing research with the University of Oxford’s Institute of Biomedical Engineering.

Therapeutic: Orthopedics & Spine

PMD Solutions (Cork, Ireland) was founded by Myles Murray to fill the fundamental clinical need to measure patients rate of breathing, which if amiss, is a significant indicator of early deterioration. RespiraSense is a wireless, discreet, continuous respiratory rate monitor that eliminates Respiratory Rate monitoring’s subjectivity and produces this information efficiently to understand a user-friendly platform. PMD Solution’s creation of RespiraSense has revolutionised the early diagnosis and intervention of medical events, making every breath count.

Therapeutic: Respiratory & Remote Patient Monitoring

Prenosis, Inc. (Chicago, IL, USA) is commercializing ImmunixTM, a precision medicine platform that can map out a patient’s immune system in minutes, using machine learning algorithms trained on NOSIS, a proprietary dataset generated by Prenosis. NOSIS is the world’s largest and most rapidly growing dataset with pristine time series biological data coupled to clinical data and patient outcomes. ImmunixTM has the potential to transform the $1.1B hospital clinical decision support market, the $3B immunotherapy market, and the $10B health & wellness market.

Pristine Surgical (Manchester, NH, USA) has developed an integrated surgical imaging system for rigid endoscopy (arthroscopy and laparoscopy) which provides a crystal-clear HD view in a clean, low cost, hassle free single-use device.

Therapeutic: Surgery

Radiance Therapeutics (Tucson, AZ, USA) is commercializing an innovation from University College London/ Moorfields Eye Hospital to address the critical unmet need of high failure rates in glaucoma filtration surgery. The RadianceTx device utilizes beta therapy; a therapeutic modality clinically proven in Randomized Controlled Trials to significantly improve glaucoma surgical outcomes. This disruptive technology has the potential to revolutionize the treatment of glaucoma; RadianceTx is a compelling opportunity to enter the growing ophthalmic device market with a lead technology.

Therapeutic: Ophthalmology

RSP Systems (Odense, Funen, Denmark) is a Danish medical technology company focused on bringing innovative glucose monitors to people with diabetes. The all-in-one device uses Raman spectroscopy to painlessly and accurately measure glucose levels in interstitial fluid.

Therapeutic: Diabetes

Sense Neuro Diagnostics (Cincinnati, OH, USA) Sense Diagnostics has developed technology that can 1) detect and distinguish between all stroke subtypes in pre-hospital and emergency department environments, and 2) monitor ongoing brain injury susceptible to expanding hemorrhage accurately, objectively, continuously and in real time. Our initial focus is on stroke and traumatic brain injury, where time to proper treatment is critical, and delays can result in disability or death. We have developed one device to effectively triage patients in the field and ED by determining stroke by subtype and bleeding from a TBI, and another for monitoring in the Neuro ICU.  Sense technology performs a single scan of 720 data points in 2.5 seconds, and detects bleeds as small as 1 ml.

Therapeutic: Neurovascular

Sonavex, Inc. (Baltimore, MD, USA) is a commercial stage Johns Hopkins spin-out. The company’s first technology is a dual-component system comprising an FDA-cleared bioresorbable implant (EchoMark) with >90% margins and an FDA-cleared imaging device (EchoSure) to detect post-operative vascular complications in reconstructive, transplant, and vascular surgeries prior to catastrophic surgical failures that represent a $2B annual market and cost hospitals up to $174,000 per instance. Sonavex is currently seeking growth capital.

Therapeutic: Imaging

SoniVie (Boston, MA, USA) TIVUS is in intravascular procedure that results in denervation of the sympathetic nerves of the pulmonary arteries to treat pulmonary hypertension. A one-time treatment can provide 12-24 months of disease control.

Therapeutic: Pulmonary

STENTiT (Eindhoven, The Netherlands) addresses the unmet need of sustained vascular repair, with a unique concept of regenerative stents. Our devices are entirely composed of bioresorbable microfibers, which can be implanted minimally invasive, providing structural support to the affected artery. Patients own blood cells infiltrate into our special designed microfiber structure, triggering a natural healing response. The stent will safely resorb over time, while rebuilding new vascular tissue from the inside-out, leaving behind a regenerated artery to last a lifetime.

Therapeutic: Cardiovascular & Regenerative Medicine

Venock (New York, NY, USA) is MedTech startup with headquarters in New York City and operations in Munich, Germany. The company is specializing in vascular closure of very large bore access sites (>8 mm) from transcatheter therapies. Primarily, at this juncture, the company is focusing on large bore VENOUS closure. Both because this is a currently unmet need in the industry with a >$2B market, and because this is a much more straightforward path to commercialization in terms of regulatory clinical studies. However, Venock is designing its device so that it does close large bore access sites in BOTH veins and arteries. The current method of closing large bore venous access sites is manual compression, which is time consuming, costly, and results in considerable amount of patient discomfort. The Venock system will attain full closure in 1 minute.

Therapeutic: Cardiovascular

Ventinova Medical (Eindhoven, The Netherlands) is a company that develops and markets innovative products for airway management and patient ventilation. Ventinova Medical develops and markets innovative medical devices. The products that are currently on the market are: mechanical ventilator, Evone; manual ventilator, Ventrain; the ultrathin tube, Tritube; and 2 mm transtracheal catheter, Cricath.

Therapuetic: Respiratory

Zendra Health (Dublin, Ireland) helps MedTech companies move 'beyond the device' by developing companion apps for medical devices at a fraction of the time and cost through Medical Grade Companion App Builder, an award-winning no-code platform. Our team has built digital health solutions for Apple and Stanford University and are pioneers in digital health. Are you looking to enhance the offering of care and deliver transformational insights for your medical device through a medical-grade companion app? Connect with us to discuss further.

Therapeutic: Digital Health, Digital Biomarkers, Diagnostics, & Remote Patient Monitoring

Zoan BioMed (Connemara, Galway, Ireland) is a highly innovative orthopedics company focused on developing the next generation Bone graft materials from sustainable reared tropical marine coral. We are developing a highly innovative range of products ranging from bone graft substitutes, infection control bone grafts, 3D print bio-materials and replacement allograft struts. Our launch Product ZOANG03, a naturally porous, integrally strong bone graft substitute, is scheduled for FDA 510(k) submission in Q4 2020, fully supported by manufacturing capabilities operating to ISO 13485.

Therapeutic: Orthopedics